18 February 2016
Joint Position Statement by HAI, The Commons Network and Public Citizen.Summary
Both the European Union (EU) and the United States (US) are confronted with increasingly high medicine prices. European Member States are facing a looming access to medicines crisis as they struggle to afford new, patented, high-priced medicines. The Transatlantic Trade and Investment Partnership Agreement (TTIP), now under negotiation, could hamper needed changes towards affordability, needs-driven innovation and alternative incentive structures.
31 March 2016
Trilogues are meetings held between representatives of the European Parliament, Council and European Commission to discuss policy and legislative proposals. In a joint submission to a public consultation by the European Ombudsman, HAI, ISDB, the Medicines in Europe Forum and the Nordic Cochrane Centre recommend the establishment of a register of Trilogue documents, in order to level the playing field in favour of the public interest.
Amsterdam, 18 April 2016
20 civil society organisations including the Medicines in Europe Forum and ISDB announced their strong support for the Dutch European Union (EU) Presidency's critique of the current over-protection and misuse of intellectual property and related rights for pharmaceuticals. They also expressed support for efforts to better balance rewards for innovation against concerns over the affordability of medicines.
Brussels, 2 June 2016
25 Civil Society organisations, including the Medicines in Europe Forum and the International Society of Drug Bulletins, call on Member States to resist pressure from the pharmaceutical industry to eliminate critical elements of proposed European Union (EU) Council Conclusions that would improve the balance between innovation and patients' access to affordable medicines.
Brussels, 31 August 2016
In a joint press release, the International Society of Drug Bulletins, the Medicines in Europe Forum and the Nordic Cochrane Centre observe that EMA's report on "adaptive pathways" delivers little factual data but seems to indicate disappointing results for the controversial pilot project.